Literature DB >> 21742003

Novel fusion protein protects against adherence and toxicity of enterohemorrhagic Escherichia coli O157:H7 in mice.

Xiang Gao1, Kun Cai, Tao Li, Qin Wang, Xiaojun Hou, Renmao Tian, Hao Liu, Wei Tu, Le Xiao, Lihua Fang, Sen Luo, Yuenan Liu, Hui Wang.   

Abstract

Infection with Escherichia coli (E. coli) O157:H7 may develop into bloody diarrhea, or hemorrhagic uremic syndrome (HUS), which usually causes kidney failure or even death. Considered as the pathogenesis mechanism of E. coli O157:H7 infection, attachment or adhesion that is directly mediated by intimin is the first step of E. coli O157:H7 interaction with its host, and all these serious sequelae are mainly due to Shiga toxins (Stxs) released by E. coli O157:H7. In this study, a novel SSI fusion protein that contains the critical toxin-antigens Stx2B and Stx1B, and the critical adhesion-antigen fragment Int281 was constructed. The protein induced complete immune protection, with both anti-toxin and anti-adhesion effects. The dominant increase in IgG1 and the high level of Th2-typical cytokine (IL-4 and IL-10) expression showed that SSI significantly induced Th2-mediated humoral immune response. In the mouse model, the SSI fusion protein not only elicited neutralizing antibodies against both Stx1 and Stx2 toxins, but also induced a high level of anti-adhesion antibodies. The SSI-immunized mice did not show any pathologic changes. SSI provides evident protection with two-time immunization against a highly lethal dose of E. coli O157:H7.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21742003     DOI: 10.1016/j.vaccine.2011.06.106

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  14 in total

1.  Immunization of mice with chimeric antigens displaying selected epitopes confers protection against intestinal colonization and renal damage caused by Shiga toxin-producing Escherichia coli.

Authors:  David A Montero; Felipe Del Canto; Juan C Salazar; Sandra Céspedes; Leandro Cádiz; Mauricio Arenas-Salinas; José Reyes; Ángel Oñate; Roberto M Vidal
Journal:  NPJ Vaccines       Date:  2020-03-12       Impact factor: 7.344

2.  Oral Administration with Live Attenuated Citrobacter rodentium Protects Immunocompromised Mice from Lethal Infection.

Authors:  Shuyu Wang; Xue Xia; Yue Liu; Fengyi Wan
Journal:  Infect Immun       Date:  2022-07-05       Impact factor: 3.609

Review 3.  Recent advances in understanding enteric pathogenic Escherichia coli.

Authors:  Matthew A Croxen; Robyn J Law; Roland Scholz; Kristie M Keeney; Marta Wlodarska; B Brett Finlay
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

Review 4.  Advances in the development of enterohemorrhagic Escherichia coli vaccines using murine models of infection.

Authors:  Victor A Garcia-Angulo; Anjana Kalita; Alfredo G Torres
Journal:  Vaccine       Date:  2013-05-22       Impact factor: 3.641

5.  Comparative genomics and immunoinformatics approach for the identification of vaccine candidates for enterohemorrhagic Escherichia coli O157:H7.

Authors:  Víctor A García-Angulo; Anjana Kalita; Mridul Kalita; Luis Lozano; Alfredo G Torres
Journal:  Infect Immun       Date:  2014-03-04       Impact factor: 3.441

6.  Novel fusion antigen displayed-bacterial ghosts vaccine candidate against infection of Escherichia coli O157:H7.

Authors:  Kun Cai; Wei Tu; Yuenan Liu; Tao Li; Hui Wang
Journal:  Sci Rep       Date:  2015-12-02       Impact factor: 4.379

Review 7.  Targeting the bacteria-host interface: strategies in anti-adhesion therapy.

Authors:  Anne Marie Krachler; Kim Orth
Journal:  Virulence       Date:  2013-05-15       Impact factor: 5.882

8.  A recombinant subunit vaccine for the control of ovine psoroptic mange (sheep scab).

Authors:  Stewart T G Burgess; Francesca Nunn; Mintu Nath; David Frew; Beth Wells; Edward J Marr; John F Huntley; Tom N McNeilly; Alasdair J Nisbet
Journal:  Vet Res       Date:  2016-02-09       Impact factor: 3.683

9.  Antibodies Directed against Shiga-Toxin Producing Escherichia coli Serotype O103 Type III Secreted Proteins Block Adherence of Heterologous STEC Serotypes to HEp-2 Cells.

Authors:  Taseen S Desin; Hugh G Townsend; Andrew A Potter
Journal:  PLoS One       Date:  2015-10-09       Impact factor: 3.240

10.  A Poly-N-acetylglucosamine-Shiga toxin broad-spectrum conjugate vaccine for Shiga toxin-producing Escherichia coli.

Authors:  Xi Lu; David Skurnik; Clarissa Pozzi; Damien Roux; Colette Cywes-Bentley; Jennifer M Ritchie; Diana Munera; Marina L Gening; Yury E Tsvetkov; Nikolay E Nifantiev; Matthew K Waldor; Gerald B Pier
Journal:  MBio       Date:  2014-03-25       Impact factor: 7.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.